Tanvex BioPharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Stephen Lam
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.2yrs |
Recent management updates
CEO
Stephen Lam
Mr. Stephen Lam is Chief Executive Officer of Tanvex BioPharma, Inc. from September 5, 2024 and serves as its Director from March 27, 2025.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| Founder & Honorary Chairman | no data | NT$111.00k | 0.60% NT$ 78.9m | |
| CFO & Corporate Governance Officer | less than a year | no data | no data | |
| VP of Finance | no data | no data | no data | |
| Accounting Officer | 1.3yrs | no data | no data | |
| Chief Technology Officer | 10.4yrs | no data | no data | |
| Director of Sales & Marketing | no data | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Chief Internal Auditor | less than a year | no data | no data | |
| Secretary | no data | no data | no data |
Experienced Management: 6541's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | no data | |
| Founder & Honorary Chairman | 11.9yrs | NT$111.00k | 0.60% NT$ 78.9m | |
| Director | 1.4yrs | NT$5.00k | no data | |
| Director | 11.6yrs | NT$25.00k | 0.0069% NT$ 903.1k | |
| Chairman of the Board | less than a year | no data | no data | |
| Independent Director | 3.8yrs | NT$687.00k | no data | |
| Independent Director | 2.9yrs | NT$570.00k | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.9yrs | NT$622.00k | no data | |
| Independent Director | less than a year | no data | no data |
Experienced Board: 6541's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 15:38 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tanvex BioPharma, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| null null | KGI Securities Co. Ltd. |